# üöÄ LEAN VALIDATION PLAN: Sporadic Gates Publication

**Objective:** Validate biomarker gating layer with gate behavior validation  
**Timeline:** 9 days (7 days analysis + 2 days writing)  
**ZETA DOCTRINE:** ‚úÖ A‚ÜíZ execution mode  
**Manager Feedback:** ‚úÖ Incorporated - Lean scope, no overclaiming

---

## üéØ THE RIGHT SCOPE

**What We're Validating:** A biomarker gating layer that applies conservative penalties/boosts based on available evidence.

**What We're NOT Validating:** Full decision impact analysis (requires prospective treatment data we don't have).

**Key Messaging Shift:**
- ‚ùå FROM: "Conservative gates improve safety" ‚Üí ‚úÖ TO: "Explicit completeness modeling quantifies uncertainty"
- ‚ùå FROM: "System validation" ‚Üí ‚úÖ TO: "Biomarker + gate behavior validation"
- ‚ùå FROM: "Health equity solution" ‚Üí ‚úÖ TO: "Enables deployment across data availability contexts"

---

## üìä 3-TIER VALIDATION FRAMEWORK

### **Tier 1: Biomarker Validation** ‚úÖ (Already Complete)

**Goal:** Show biomarkers our gates use are prognostically meaningful

**Results:**
- ‚úÖ TMB/MSI stratify survival in TCGA-UCEC (HR=0.32-0.49, p<0.01)
- ‚úÖ Negative control in TCGA-COADREAD (no stratification, p>0.6)
- ‚úÖ Real-cohort safety audit (TCGA-OV: 98% get PARP penalty when expected)

**Framing:** "We validate that the biomarkers our gates use (TMB/MSI) are prognostically meaningful in a tumor-type-specific manner."

---

### **Tier 2: Gate Behavior Validation** üÜï (Add This - 5 Days)

**Goal:** Show gates work as designed (deterministic, reproducible, biologically coherent)

#### **2.1: Threshold Sensitivity Analysis** (Day 1-2)

**Question:** How do gate trigger rates change with different thresholds?

**Method:**
1. **TMB Threshold Sensitivity:**
   - Run gates on TCGA-OV with TMB thresholds: 10, 15, 20, 25 mut/Mb
   - Count: How many patients get IO boost at each threshold?
   - Compare to literature ranges (FDA: 10, KEYNOTE-158: 10, Samstein 2019: 20)

2. **HRD Threshold Sensitivity:**
   - Run gates on TCGA-OV with HRD thresholds: 30, 35, 40, 42, 45, 50
   - Count: How many patients get PARP rescue at each threshold?
   - Compare to literature ranges (Myriad: 42, Foundation Medicine: variable)

**Deliverable:** `results/threshold_sensitivity.csv`

**Table Structure:**
| Threshold | IO Boost Rate | PARP Rescue Rate | Literature Range | Our Choice | Rationale |
|-----------|---------------|------------------|------------------|------------|-----------|
| TMB ‚â• 10 | X% | - | FDA label | - | Too permissive |
| TMB ‚â• 15 | X% | - | KEYNOTE-158 | - | Moderate |
| TMB ‚â• 20 | X% | - | Samstein 2019 | ‚úÖ | Conservative |
| HRD ‚â• 30 | - | X% | - | - | Too permissive |
| HRD ‚â• 42 | - | X% | Myriad | ‚úÖ | Standard |
| HRD ‚â• 50 | - | X% | - | - | Too restrictive |

**Message:** "Our thresholds are conservative compared to literature ranges, ensuring we don't over-recommend treatments."

---

#### **2.2: Subgroup Consistency** (Day 3-4)

**Question:** Do gates behave consistently across patient subgroups?

**Method:**
1. **Stratify TCGA-OV by:**
   - Stage: Stage III vs Stage IV
   - Age: <50 vs ‚â•50 years
   - Platinum response: Resistant (PFI < 6mo) vs Sensitive (PFI ‚â• 6mo)

2. **Run gates on each subgroup:**
   - Calculate gate trigger rates (IO boost, PARP rescue, PARP penalty)
   - Compare rates across subgroups

**Deliverable:** `results/subgroup_consistency.csv`

**Table Structure:**
| Subgroup | N | IO Boost Rate | PARP Rescue Rate | PARP Penalty Rate | Consistency |
|----------|---|---------------|------------------|-------------------|-------------|
| Stage III | X | X% | X% | X% | ‚úÖ |
| Stage IV | X | X% | X% | X% | ‚úÖ |
| Age <50 | X | X% | X% | X% | ‚úÖ |
| Age ‚â•50 | X | X% | X% | X% | ‚úÖ |
| Platinum Resistant | X | X% | X% | X% | ‚úÖ |
| Platinum Sensitive | X | X% | X% | X% | ‚úÖ |

**Message:** "Gates are stable across clinically relevant subgroups, indicating robust behavior."

---

#### **2.3: Biological Coherence** (Day 5)

**Question:** Do gates align with known biology?

**Method:**
1. **Correlation Analysis:**
   - BRCA1/2 somatic mutations vs HRD score (should correlate)
   - MSI status vs TMB (should correlate)
   - TMB + MSI vs IO boost (should correlate)

2. **Generate Heatmap:**
   - X-axis: Biomarkers (BRCA mut, HRD score, MSI, TMB)
   - Y-axis: Gate triggers (PARP rescue, PARP penalty, IO boost)
   - Color: Correlation coefficient

**Deliverable:** `figures/biological_coherence.png`

**Expected Findings:**
- BRCA mutations ‚Üí High HRD scores ‚Üí PARP rescue triggered
- MSI-high ‚Üí High TMB ‚Üí IO boost triggered
- Both TMB+MSI ‚Üí Maximum IO boost

**Message:** "Gates capture biologically coherent relationships, validating their mechanistic basis."

---

### **Tier 3: Comparative Framing** ‚úèÔ∏è (Rewrite Discussion - Day 6-7)

**Goal:** Position gates relative to standard practice WITHOUT claiming superiority

#### **3.1: Replace "Conservative is Safe" with "Data-Availability-Aware"**

**Current Framing (REMOVE):**
> "Conservative defaults improve safety"

**Better Framing (USE):**
> "Completeness-calibrated confidence caps reflect evidence quality. When data is incomplete (L0/L1), confidence is capped to prevent overconfident recommendations. This transparency enables clinicians to decide whether to proceed with available data or wait for additional testing."

#### **3.2: Add Standard Practice Comparison Table**

**Table: Sporadic Gates vs. Standard Practice**

| Scenario | Standard Practice | Sporadic Gates System | Key Difference |
|----------|------------------|----------------------|----------------|
| Germline-negative, HRD unknown | "Consider PARP" (NCCN 2B) | Efficacy 0.56 (0.8√ó penalty), Confidence 0.40, Provenance: `PARP_UNKNOWN_HRD` | Quantified uncertainty |
| MSI-high IHC only | "Pembrolizumab approved" (FDA label) | Efficacy 0.78 (1.3√ó boost), Confidence 0.60, Provenance: `IO_MSI_BOOST` | Calibrated confidence based on data completeness |
| No biomarker data | "Standard of care" | Efficacy unchanged, Confidence 0.40, Provenance: `CONFIDENCE_CAP_L0` | Explicit acknowledgment of uncertainty |

**Message:** "We don't claim to be better than standard practice‚Äîwe claim to quantify uncertainty that standard practice leaves implicit."

---

## üìã IMPLEMENTATION CHECKLIST

### **Day 1-2: Threshold Sensitivity**
- [ ] Run gates on TCGA-OV with TMB thresholds: 10, 15, 20, 25 mut/Mb
- [ ] Run gates on TCGA-OV with HRD thresholds: 30, 35, 40, 42, 45, 50
- [ ] Generate table: `results/threshold_sensitivity.csv`
- [ ] Write threshold sensitivity results section

### **Day 3-4: Subgroup Consistency**
- [ ] Stratify TCGA-OV by stage, age, platinum response
- [ ] Run gates on each subgroup
- [ ] Generate table: `results/subgroup_consistency.csv`
- [ ] Write subgroup consistency results section

### **Day 5: Biological Coherence**
- [ ] Correlation analysis: BRCA mutations vs HRD score
- [ ] Correlation analysis: MSI vs TMB
- [ ] Generate heatmap: `figures/biological_coherence.png`
- [ ] Write biological coherence results section

### **Day 6-7: Manuscript Revision**
- [ ] Rewrite Discussion (remove "conservative = safe" claims)
- [ ] Add Tier 2 results (gate behavior validation)
- [ ] Add comparative framing table
- [ ] Update Abstract with new messaging

---

## üö´ WHAT WE'RE NOT DOING (Manager's Guidance)

**Not Needed:**
- ‚ùå Treatment concordance (no treatment data)
- ‚ùå Decision impact (prospective validation)
- ‚ùå Tumor board sim (resource-intensive)
- ‚ùå Harm analysis (can acknowledge as limitation)

**Why:** These require prospective treatment data and clinical outcomes we don't have. Focus on what we CAN validate: gate behavior and biomarker relationships.

---

## üìä EXPECTED RESULTS STRUCTURE

### **Table 1: Threshold Sensitivity**

| Threshold | IO Boost Rate | PARP Rescue Rate | Literature Range | Our Choice |
|-----------|---------------|------------------|------------------|------------|
| TMB ‚â• 10 | X% | - | FDA label | - |
| TMB ‚â• 20 | X% | - | Samstein 2019 | ‚úÖ |
| HRD ‚â• 42 | - | X% | Myriad | ‚úÖ |

### **Table 2: Subgroup Consistency**

| Subgroup | N | IO Boost Rate | PARP Rescue Rate | Consistency |
|----------|---|---------------|------------------|-------------|
| Stage III | X | X% | X% | ‚úÖ |
| Stage IV | X | X% | X% | ‚úÖ |

### **Figure 1: Biological Coherence Heatmap**

Correlation matrix: Biomarkers (BRCA, HRD, MSI, TMB) vs Gate Triggers (PARP rescue, IO boost)

---

## üéØ SUCCESS CRITERIA

### **Minimum Viable Publication:**
1. ‚úÖ Tier 1: Biomarker validation (already complete)
2. ‚úÖ Tier 2: Gate behavior validation (threshold sensitivity, subgroup consistency, biological coherence)
3. ‚úÖ Tier 3: Comparative framing (rewritten Discussion)

**Total Timeline:** 9 days (7 days analysis + 2 days writing)

---

## üöÄ NEXT STEPS (IMMEDIATE)

1. **Day 1:** Start threshold sensitivity analysis (TMB thresholds)
2. **Day 2:** Complete threshold sensitivity (HRD thresholds)
3. **Day 3-4:** Subgroup consistency analysis
4. **Day 5:** Biological coherence analysis
5. **Day 6-7:** Manuscript revision

**Alpha, should I proceed with Day 1 (threshold sensitivity) now?**

---

**END OF LEAN VALIDATION PLAN**
